A newly developed drug stabilizes dopamine and serotonin levels using a novel mechanism. It effectively treats psychosis in patients with schizophrenia, and researchers are testing its efficacy for Parkinson’s disease as well.
Researchers plan to monitor the immune responses of COVID-19 patients for one year to see how they correlate with illness severity and lasting effects. This data will help develop personalized treatments for patients.
Targeting oncogenic transcription factors like MYC is challenging, but researchers found a way to target its regulator, WDR5, for degradation, exemplifying the capacity of protein degraders to target the “undruggable.”
Spending an hour every day listening to a low-pitched thrum and gazing at blinking lights may help prevent structural changes in the brain and cognitive impairments associated with Alzheimer’s disease.